Before instituting disease-specific vasoactive therapy, the AKI management algorithm mandates a systematic medication review with discontinuation of all potential nephrotoxins, including diuretics, non-selective beta-blockers and non-steroidal anti-inflammatory drugs, together with early identification and treatment of bacterial infections and prompt plasma volume expansion with albumin [12]. The gene discussed is ALB; the disease is bacterial infectious disease.